Tumor News and Research

RSS

Single cancer cell could be detected in future using new test

Soon scientists will be able to detect a single cancer cell among the billions of cells that circulate in the human bloodstream. The method could detect whether the therapy has worked or even show which therapy would work best. The test depends on circulating tumor cells (CTCs) or cancer cells that have detached from the main tumor and are traveling to other parts of the body.

4 Jan 2011

Past smoking history does not affect RA patient's response to treatments

Patients with early rheumatoid arthritis (RA) who are current smokers were less likely to achieve good response to methotrexate (MTX) and tumor necrosis factor (TNF) inhibitors than those who never smoked. The study by researchers from Sweden also found that RA patients who smoked in the past did not experience a lower response to these therapies. Results of the 10-year study appear in the January 2011 issue of Arthritis & Rheumatism, a journal published by Wiley-Blackwell on behalf of the American College of Rheumatology (ACR).

4 Jan 2011

Isis commences ISIS-EIF4ERx Phase 2 studies in non-small cell lung cancer and prostate cancer

Isis Pharmaceuticals, Inc. announced the initiation of two Phase 2 studies of ISIS-EIF4ERx in patients with non-small cell lung cancer and prostate cancer. These studies are part of Isis' broad Phase 2 development program designed to evaluate ISIS-EIF4ERx in multiple types of cancer. ISIS-EIF4ERx targets eukaryotic initiation factor-4E (eIF-4E), a traditionally "undruggable" target that is thought to promote tumor growth and metastasis in many cancers.

4 Jan 2011

MGH, Veridex establish research center of excellence on circulating tumor cell technologies

Massachusetts General Hospital (MGH) has entered into a collaborative agreement with Veridex LLC to establish a center of excellence in research on circulating tumor cell (CTC) technologies. The overall goal of the agreement is to develop and commercialize novel technologies for capturing and characterizing CTCs, solid tumor cells found at extremely low levels in the bloodstream, which may offer a key to noninvasive characterization of cancer and potentially to early detection.

4 Jan 2011

CDK1 protein deactivates EZH2 enzyme that causes cancer spread

By sticking a chemical group to it at a specific site, a protein arrests an enzyme that may worsen and spread cancer, an international research team led by scientists at The University of Texas MD Anderson Cancer Center reports in the January issue of Nature Cell Biology.

4 Jan 2011

Peptide in blood and tissue inhibits growth of breast tumors

Researchers at Wake Forest University Baptist Medical Center (WFUBMC) have discovered what may become a new weapon in the fight against breast cancer. For the first time, a peptide found in blood and tissue has been shown to inhibit the growth of human breast tumors in mice, according to a study recently published in the journal Cancer Research.

4 Jan 2011

Mercator, Pepscan enter multi-program cancer research collaboration

Mercator Therapeutics, the first biopharmaceutical company to systematically use in vivo phage display technology to develop novel cancer drugs and Pepscan Therapeutics, a world leader in protein mimicry technologies for improved therapeutic peptides and anti-GPCR antibodies, today announced a multi-program research collaboration. The companies will collaborate to optimize Mercator's 'Homing Peptides' using Pepscan's proprietary CLIPS technology.

4 Jan 2011

Researchers report estrogen may increase movement of precancerous cells in oral cavity

Head and neck cancer is the sixth most common type of cancer and is on the rise in some demographic groups, including young women without any known risk factors. Now, researchers at Fox Chase Cancer Center report that estrogen may increase the movement of precancerous cells in the mouth and thus promote the spread of the disease within the oral cavity.

4 Jan 2011

FDA grants orphan drug status for Senesco's SNS01-T in treatment of multiple myeloma

Senesco Technologies, Inc., announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for the company's lead drug candidate SNS01-T for treatment of multiple myeloma.

3 Jan 2011

CEL-SCI initiates Multikine Phase III trail for head and neck cancer

CEL-SCI Corporation announced today that it has commenced its Phase III clinical trial for Multikine®, the Company's flagship immunotherapy. CEL-SCI has now completed all of the manufacturing and regulatory requirements to begin enrollment of the study.

29 Dec 2010

Exiqon announces introduction of GLP compliant services for miRNA biomarker screening

Exiqon A/S, a leading provider of technologies for biomarker detection, today announced the introduction of GLP compliant services for miRNA biomarker screening and diagnostic assay development for clinical trials.

27 Dec 2010

Gold-coated liposomes could make chemotherapy more effective without harmful side effects

University of Arizona researchers may have found a way to deliver chemotherapeutic drugs to cancer tissues in controlled doses without harming healthy body cells.

24 Dec 2010

AMPK activates autophagy by activating ATG1 enzyme

Researchers at the Salk Institute for Biological Studies have discovered how AMPK, a metabolic master switch that springs into gear when cells run low on energy, revs up a cellular recycling program to free up essential molecular building blocks in times of need.

24 Dec 2010

Growth hormone may be hazardous for middle aged and older people

A compound which acts in the opposite way as growth hormone can reverse some of the signs of aging, a research team that includes a Saint Louis University physician has shown. The finding may be counter-intuitive to some older adults who take growth hormone, thinking it will help revitalize them.

24 Dec 2010

Quercetin and resveratrol may play an important role in inflammation and insulin resistance

A study was carried out to examine the extent to which quercetin and trans-resveratrol (RSV) prevented inflammation or insulin resistance in primary cultures of human adipocytes treated with tumor necrosis factor-a (TNF-a)-an inflammatory cytokine elevated in the plasma and adipose tissue of obese, diabetic individuals. Cultures of human adipocytes were pretreated with quercetin and trans-RSV followed by treatment with TNF-a. Subsequently, gene and protein markers of inflammation and insulin resistance were measured.

24 Dec 2010

EMCTO 2011 to provide update on treatment of thoracic malignancies

The number of diagnostic and therapeutic options for patients with thoracic malignancies has markedly increased, allowing for an individualized approach based on the clinical situation and molecular characteristics of the tumor. How to best select among these options for the benefit of the patients within an integrative treatment approach will be at the core of the conference.

23 Dec 2010

Earlier diagnosis in Cowden syndrome patients predisposed to breast and kidney cancer

Researchers at Cleveland Clinic's Genomic Medicine Institute have revealed multiple genetic discoveries that may permit easier diagnosis and disease management for Cowden syndrome patients who are predisposed to breast and kidney cancer.

23 Dec 2010

Myrexis commences Azixa controlled two-arm Phase 2b clinical study in GBM

Myrexis, Inc., a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today announced it has initiated a controlled two-arm Phase 2b clinical study of Azixa (verubulin) as a front-line treatment for glioblastoma multiforme (GBM).

23 Dec 2010

Certain drugs may block tumor host interactions but do not destroy cancer cells

A class of drugs thought to kill cancer cells may in fact block "cross talk" between the cancer cell and normal immune cells, resulting in reduced cancer growth and spread-a discovery that could significantly alter the way cancer drugs are evaluated in the future.

23 Dec 2010

Patients with over expression of P-Rex1 protein are more likely to develop cancer metastasis

Overexpression or hyperactivation of ErbB cell-surface receptors drives the growth of many breast cancers. Drugs, like Herceptin, that block the receptors' signals halt tumor progression in some patients.

23 Dec 2010

Tumor News and Research

Single cancer cell could be detected in future using new test

Past smoking history does not affect RA patient's response to treatments

Isis commences ISIS-EIF4ERx Phase 2 studies in non-small cell lung cancer and prostate cancer

MGH, Veridex establish research center of excellence on circulating tumor cell technologies

CDK1 protein deactivates EZH2 enzyme that causes cancer spread

Peptide in blood and tissue inhibits growth of breast tumors

Mercator, Pepscan enter multi-program cancer research collaboration

Researchers report estrogen may increase movement of precancerous cells in oral cavity

FDA grants orphan drug status for Senesco's SNS01-T in treatment of multiple myeloma

CEL-SCI initiates Multikine Phase III trail for head and neck cancer

Exiqon announces introduction of GLP compliant services for miRNA biomarker screening

Gold-coated liposomes could make chemotherapy more effective without harmful side effects

AMPK activates autophagy by activating ATG1 enzyme

Growth hormone may be hazardous for middle aged and older people

Quercetin and resveratrol may play an important role in inflammation and insulin resistance

EMCTO 2011 to provide update on treatment of thoracic malignancies

Earlier diagnosis in Cowden syndrome patients predisposed to breast and kidney cancer

Myrexis commences Azixa controlled two-arm Phase 2b clinical study in GBM

Certain drugs may block tumor host interactions but do not destroy cancer cells

Patients with over expression of P-Rex1 protein are more likely to develop cancer metastasis

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News